ME/CFS, Butyrate, and Host Capacity: What a Severe Case Reveals About the Microbiome–Host Relationship

I have been studying the gastrointestinal physiology of ME/CFS for some time, but a severe long-duration case I am currently analyzing has pushed me to think much more carefully about what we actually mean when we say that the microbiome is abnormal in this disease. The conventional discussion of microbiome dysfunction usually begins with organisms. A stool test identifies certain bacteria as depleted, others as elevated, and perhaps a metabolite such as butyrate is low. The obvious conclusion is then to replace the missing organisms, suppress the elevated organisms, add more fermentable substrate or provide the missing metabolite directly. That interpretation can sometimes be useful, but biologically it is incomplete because it treats the microbiome as though it were an independent system rather than an ecosystem whose metabolism is continuously constrained by the physiology of the host.

The case that brought this into focus involves an adult client with long-standing ME/CFS whose illness began many years before the current gastrointestinal phenotype became dominant. Early in the course there were already signs of impaired physiological reserve, including exertional intolerance, episodes of lightheadedness, heat intolerance, nausea, fatigue and later prominent autonomic dysfunction. Over time the illness became increasingly multi-systemic, with major fluctuations in functional capacity, periods of partial improvement with extensive rest, and recurrent severe crashes. Gastrointestinal dysfunction subsequently became much more prominent, eventually including prolonged nausea, substantially reduced food intake, constipation, a SIBO phenotype, severe abdominal symptoms, highly restricted food tolerance and recurrent systemic reactions associated with eating.

The severity of the illness eventually progressed to the point that the client became largely bedbound. Food tolerance narrowed dramatically, and interventions that would normally be regarded as relatively benign began producing disproportionate reactions. Very small doses of supplements intended to support gastrointestinal, immune or mast-cell physiology could trigger severe neurological, gastrointestinal or autonomic symptoms. Some reactions occurred at doses far below those normally used therapeutically. Certain foods could also provoke unexpectedly intense symptoms. This created a situation in which the problem was no longer simply identifying potentially useful interventions. The more important problem was understanding why the system appeared unable to tolerate additional metabolic or signaling input.

That distinction became particularly interesting when I reviewed the client’s stool chemistry. A comprehensive stool analysis demonstrated a reduced total short-chain fatty acid pool together with low absolute butyrate. Total fecal SCFAs measured 3.6 mg/mL against a laboratory reference interval of 5.0–16.0 mg/mL. Absolute butyrate measured 0.52 mg/mL against a reference interval of 0.8–4.0 mg/mL. Acetate represented 49% of the SCFA pool, slightly below the laboratory reference percentage, while propionate represented 32%, above the laboratory range. Butyrate represented 15% of total SCFAs, which remained within the laboratory’s percentage reference interval.

That combination is considerably more informative than simply labeling butyrate normal or abnormal. The absolute quantity of butyrate was clearly reduced and the total measured SCFA pool was also reduced, yet butyrate still occupied a nominally normal proportion of that depleted pool. This illustrates an important problem in microbiome interpretation: relative composition is not the same thing as absolute metabolic output. Fifteen percent of a large SCFA pool and fifteen percent of a severely depleted SCFA pool do not represent the same physiological exposure. A percentage can therefore appear reassuring while the actual amount of metabolite available to the intestinal ecosystem has fallen substantially.

This finding immediately reminded me of the 2023 study by Guo and colleagues published in Cell Host & Microbe, titled “Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME/CFS.” The investigators studied 106 people with ME/CFS and 91 healthy controls using shotgun metagenomics, quantitative PCR, microbial network analysis and direct measurement of fecal short-chain fatty acids. The importance of the paper is that the investigators did not stop at identifying differences in bacterial abundance. They followed the abnormality into microbial metabolic function.

Two major butyrate-producing organisms, Faecalibacterium prausnitzii and Eubacterium rectale, were reduced in ME/CFS. More importantly, genes involved in microbial butyrate production were also depleted. Much of human colonic butyrate production proceeds through the acetyl-CoA pathway, eventually generating butyryl-CoA. Many dominant human butyrate producers complete the final step using butyryl-CoA CoA-transferase, encoded by the gene commonly referred to as but. Guo and colleagues found reduced representation of this pathway and independently confirmed lower but gene copy numbers using quantitative PCR. They then directly measured fecal metabolites and found reduced butyrate and acetate. Lower abundance of Faecalibacterium prausnitzii was also associated with greater fatigue severity.

The strength of that study is the convergence across biological levels. The investigators found reduced butyrate-producing organisms, reduced functional genetic capacity for butyrate synthesis, reduced copies of a key terminal-pathway gene and lower measured butyrate in stool. The abnormality therefore extended beyond taxonomy into actual microbial metabolic function.

The anonymized case I am describing cannot be treated as a replication of the Guo study. The clinical stool assay did not use the same shotgun metagenomic platform and did not quantify the same functional genes. It also did not provide an equivalent species-level quantitative assessment of F. prausnitzii or E. rectale. The defensible comparison is therefore functional rather than taxonomic. The research cohort demonstrated reduced microbial butyrate-producing capacity and lower fecal butyrate, while this individual severe ME/CFS case independently demonstrated a reduced total SCFA pool and low absolute butyrate.

The client’s additional stool findings provide context but must be interpreted carefully. Bifidobacterium family was reported at a relatively low semiquantitative culture level, while several other broad bacterial groups were more abundant. Culture results cannot be equated with shotgun sequencing and cannot establish the absolute in-vivo abundance or metabolic activity of those organisms. Even so, the low Bifidobacterium signal is mechanistically interesting because microbial fermentation is highly dependent on cross-feeding. Primary fermenters can generate acetate and lactate that are subsequently used by other organisms to produce downstream metabolites such as butyrate. A butyrate-producing organism therefore does not need to disappear completely for butyrate production to fall. If upstream substrate production or cross-feeding collapses, metabolic output can decline even when the downstream organism remains detectable.

This is one of the most important concepts missing from routine stool interpretation. Taxonomic presence does not equal metabolic flux. A bacterium may possess the enzymes required to produce butyrate but generate little of it if fermentable substrate is scarce, acetate availability is reduced, pH is unfavorable, competing organisms consume the same substrates, bile-acid composition has changed, intestinal transit is abnormal or the surrounding redox environment no longer supports normal fermentation. A stool report can tell us something about what is present, but it does not automatically tell us what those organisms are doing per unit time.

The clinical history makes substrate limitation particularly relevant. Severe food reactivity progressively narrowed the client’s tolerated diet. When dietary diversity collapses, the microbiome loses access to many microbiota-accessible carbohydrates that normally reach the colon. Resistant starches, fermentable fibers and other complex substrates provide the carbon required for saccharolytic fermentation. If less substrate arrives, primary fermentation decreases, acetate and lactate cross-feeding can fall, secondary fermentation weakens and total SCFA production can decline. In that situation, the microbiome can look metabolically depleted partly because disease has changed the diet that sustains it.

This creates a bidirectional problem. Low SCFA production may contribute to impaired intestinal physiology, but impaired intestinal physiology and dietary restriction can also produce low SCFA output. Both directions can operate simultaneously.

Transit adds another major variable. The case includes a period of markedly reduced food intake accompanied by severe constipation, while the broader phenotype includes substantial autonomic dysfunction. Gastrointestinal motility is therefore unlikely to be an incidental factor. Transit determines how long fermentable substrates remain available, where fermentation occurs, how gases accumulate, how bile acids are transformed and which organisms gain a competitive advantage. A microbiome cannot be interpreted independently from the physical environment created by gastrointestinal motility.

The stool chemistry is also informative because the low SCFA pattern did not occur alongside obvious severe inflammatory enteropathy. Calprotectin, lactoferrin and lysozyme were within the laboratory’s reported ranges. Pancreatic elastase remained above the laboratory threshold used to flag pancreatic insufficiency, and fecal fat was not detected. That does not exclude intestinal dysfunction, but it means that the low SCFA phenotype in this sample was not simply accompanied by a dramatic high-calprotectin inflammatory pattern or overt pancreatic failure. The metabolic ecology itself deserves attention.

This is where my Host Capacity framework extends the Guo findings one layer further. The Guo study demonstrates a microbial production problem. It does not determine whether the host receiving those microbial metabolites is still capable of using them normally. Production and utilization are separate biological variables.

Butyrate is often described simply as fuel for colonocytes, but that phrase understates its importance. Mature colonocytes are highly specialized metabolically and preferentially oxidize short-chain fatty acids, particularly butyrate. Butyrate can enter epithelial cells through transport systems including MCT1 and SMCT1. Once inside the colonocyte, it enters mitochondrial metabolism, generating acetyl-CoA and reducing equivalents that feed the TCA cycle and electron transport chain.

The final electron acceptor in mitochondrial oxidative phosphorylation is molecular oxygen. That means efficient butyrate oxidation results in substantial oxygen consumption by the intestinal epithelium. This is not merely relevant to cellular ATP production. It is central to the ecology of the colon.

The colonic epithelium sits between oxygenated tissue supplied by the circulation and a luminal ecosystem dominated by obligate anaerobes. The host therefore needs to prevent excessive oxygen from reaching the lumen. Mitochondrial respiration in colonocytes helps perform this function by consuming oxygen before it can diffuse outward in large amounts. Efficient oxidative metabolism helps preserve a state of physiological epithelial hypoxia and maintains the steep oxygen gradient required by anaerobic microbial communities.

This creates an elegant reciprocal relationship. Anaerobic microorganisms ferment dietary substrates and generate butyrate. Colonocytes absorb and oxidize the butyrate. Mitochondrial oxidation consumes oxygen. Reduced oxygen availability at the luminal surface preserves an ecological advantage for strict anaerobic organisms, including many butyrate producers. Those organisms then continue supplying metabolites to the epithelial cells that maintain their habitat.

The microbiome therefore supports host metabolism, while host metabolism simultaneously supports the microbiome.

This changes the interpretation of dysbiosis. If microbial butyrate production declines, colonocytes lose part of their preferred oxidative substrate supply. If epithelial mitochondrial metabolism is also compromised, oxygen consumption can fall further. More oxygen can then become available near the luminal surface. Even relatively small changes in oxygen availability can alter microbial competition because strict anaerobes and facultative organisms operate under fundamentally different energetic constraints.

The PPAR-γ–iNOS–nitrate axis is particularly relevant here. Butyrate-associated metabolism promotes PPAR-γ activity in differentiated colonocytes and supports an oxidative metabolic phenotype. When this state deteriorates and inflammatory signaling becomes dominant, inducible nitric oxide synthase can increase nitric oxide production. Downstream reactions can increase nitrate availability. Facultative organisms capable of nitrate respiration can use this electron acceptor to generate energy through respiratory metabolism, providing an enormous competitive advantage over organisms dependent predominantly on fermentation.

The system can therefore become self-reinforcing. Reduced obligate-anaerobic fermentation decreases butyrate availability. Lower butyrate supply weakens colonocyte oxidative metabolism and PPAR-γ-associated metabolic programming. Lower mitochondrial respiration reduces epithelial oxygen consumption. Increased oxygen and nitrate availability favor organisms capable of respiratory metabolism. Their products can increase innate immune signaling and inflammatory activation. Inflammation increases iNOS activity and oxidative and nitrosative stress, which can further impair mitochondrial respiration. The host then becomes even less capable of maintaining the anaerobic environment required by the organisms that originally supplied its epithelial fuel.

At that stage dysbiosis is no longer simply an abnormal bacterial population that needs to be eradicated. It is an ecological state maintained by both microbial and host physiology.

This also changes the way antimicrobial therapy should be conceptualized. Suppressing an organism does not necessarily remove the environmental conditions that selected it. If the underlying oxygen gradient, nitrate availability, bile-acid environment, gastrointestinal transit and substrate distribution remain unchanged, organisms adapted to those conditions retain an ecological advantage. Once antimicrobial pressure is removed, the ecosystem can drift back toward the same configuration. Recurrent dysbiosis may therefore represent recurrent ecological selection rather than repeated independent infection.

In a severely treatment-sensitive patient, this distinction becomes even more important because repeated antimicrobial pressure can also reduce organisms involved in cross-feeding and functional redundancy. Healthy butyrate production does not depend on one bacterium. Multiple organisms across several phylogenetic groups contribute to overlapping fermentation pathways. If several disappear while only one remains, total production may continue but become much more fragile. The ecosystem loses redundancy, meaning changes in diet, transit or substrate availability have a much larger effect on overall metabolic output.

The redox environment adds another layer. The phrase oxidative stress is often used nonspecifically, but particular chemical reactions matter here. Superoxide generated through dysfunctional mitochondrial electron transfer can react rapidly with nitric oxide to form peroxynitrite. Peroxynitrite can damage iron-sulfur clusters, which are essential cofactors in multiple mitochondrial enzymes, including aconitase and components of the respiratory chain. Damage to these structures can impair electron flow and increase electron leakage, generating additional superoxide. If inflammatory iNOS activity simultaneously supplies more nitric oxide, a positive feedback loop can emerge in which mitochondrial dysfunction generates the chemistry that further damages mitochondria.

A metabolically impaired colonocyte then consumes less oxygen, making the microbial ecological problem worse.

Hydrogen sulfide provides another useful example of Host Capacity. H₂S is a normal signaling molecule at physiological concentrations, and colonocytes possess a mitochondrial sulfide oxidation system capable of clearing it. The relevant biological variable is therefore not simply whether sulfide-producing organisms are present. It is whether sulfide production exceeds epithelial clearance capacity. At sufficiently high exposure relative to detoxification, sulfide can inhibit mitochondrial respiration and short-chain fatty acid oxidation. A resilient epithelial cell may accommodate the exposure, whereas a cell already operating close to its respiratory limit may not.

The same production-versus-clearance principle applies throughout intestinal physiology. Histamine biology depends not only on histamine production but on DAO, HNMT, epithelial integrity, mast-cell release and vascular responsiveness. Bile-acid signaling depends not only on hepatic synthesis but on conjugation, microbial transformation, enterohepatic recycling and receptor activation. Oxalate exposure depends on intake, microbial degradation, intestinal absorption and renal clearance. Butyrate should be viewed in the same way. Production alone does not determine physiological effect.

This is why low stool butyrate cannot automatically be translated into aggressive butyrate supplementation. The microbial supply may be deficient, but the epithelial machinery that receives that supply may also be constrained. A large increase in substrate or metabolite delivery can create a rapid increase in biochemical flux, and a severely reactive system may not have the reserve to process that change smoothly.

The same limitation applies to fiber. Fiber is often discussed as though it produces one universally beneficial response. Its effect depends on molecular structure, dose, cooking method, transit, intestinal compartment and the organisms present to ferment it. A resistant starch reaching the colon of a person with an intact anaerobic ecosystem may enhance useful fermentation. The same substrate in someone with impaired small-intestinal clearance may undergo excessive fermentation proximally, increasing gas, distension and osmotic load before much of it ever reaches the colon.

The anatomical location of fermentation therefore matters as much as the amount of fermentation.

This makes food preparation biologically relevant in highly reactive patients. Cooking changes plant cell walls and starch accessibility. Cooling can increase resistant starch through retrogradation in certain foods. Reheating changes that structure again. Blending reduces particle size and changes digestion kinetics. Portion size determines total substrate load. Food storage can alter biogenic amine content in susceptible foods. In a metabolically resilient person these distinctions may produce relatively small effects. In a system operating near a threshold, they may determine whether a food is tolerated.

Bile-acid biology creates another reciprocal loop. The liver synthesizes primary bile acids and delivers them to the intestine. Microorganisms then deconjugate and chemically transform them into a broad range of secondary bile acids. These molecules signal through receptors including FXR and TGR5, influencing epithelial physiology, metabolic regulation, immune signaling, enteroendocrine function and motility. The host therefore shapes microbial ecology through bile secretion, while the microbiome modifies the bile-acid signals received by the host.

Transit strongly influences this process because microbial bile-acid transformations require time. Autonomic dysfunction changes transit. Transit changes microbial exposure to bile acids. Bile-acid signaling can then feed back into motility and epithelial physiology. What appears to be a microbiome abnormality can therefore be partly an autonomic and gastrointestinal motor abnormality expressed through microbial ecology.

Tryptophan provides another example of reciprocal host-microbial metabolism. Dietary tryptophan can enter host serotonin synthesis, the kynurenine pathway or microbial indole metabolism. Certain microbial indoles activate the aryl hydrocarbon receptor, which participates in mucosal immune regulation and interacts with IL-22-associated epithelial defense programs. A change in microbial ecology therefore changes the ligand environment presented to the immune system, while changes in epithelial and immune signaling reshape microbial selection.

Mast cells fit naturally into the same network. They reside close to epithelial surfaces, blood vessels and peripheral nerves and can respond to neuropeptides, cytokines, complement fragments, tissue damage and microbial products. Barrier dysfunction can increase exposure to luminal molecules, while mast-cell mediators can alter permeability, vascular tone, secretion, enteric nerve signaling and smooth-muscle behavior. Autonomic dysfunction influences many of those same physiological variables from another direction. The result can be a self-amplifying system in which gastrointestinal, immune, vascular and neurological symptoms become increasingly difficult to separate.

The important point is that this anonymized client’s low SCFA state cannot be interpreted as proof that butyrate deficiency initiated the entire illness. Significant autonomic and exertional abnormalities existed long before the most severe gastrointestinal deterioration. The intestinal phenotype became more pronounced over time, after years of systemic illness. Dietary restriction, prolonged nausea, reduced intake, constipation, autonomic dysfunction and repeated treatment all likely shaped the microbial ecosystem measured later.

The microbiome is therefore both a potential contributor to disease and a biological record of what has happened to the host.

This distinction is essential because a downstream abnormality can later become a driver of persistence. The mechanism that initiates a chronic illness does not need to remain the dominant mechanism years later. An infection may alter immune or autonomic function. Autonomic dysfunction can change gastrointestinal motility. Altered motility changes fermentation geography and bile-acid transformation. Food reactions progressively reduce dietary substrate diversity. Reduced substrate lowers SCFA production. Lower SCFA availability can weaken colonocyte oxidative metabolism. Reduced epithelial respiration changes the oxygen environment. The altered oxygen environment selects a different microbial ecosystem. That ecosystem then generates a different set of metabolites and immune signals.

Over time the system can become increasingly self-maintaining even if the original trigger is gone.

This is where the Guo study and this severe case converge most meaningfully. Guo and colleagues demonstrated that deficient microbial butyrate-producing capacity exists in ME/CFS at the population level. The individual case demonstrates that a profoundly reduced SCFA and butyrate phenotype can also occur in severe long-duration disease. What the case additionally shows is why that finding cannot be interpreted independently of host physiology. By the time the stool sample was obtained, years of autonomic dysfunction, dietary narrowing, gastrointestinal disturbance and severe systemic illness had already reshaped the biological environment in which the microbiome existed.

The next step in ME/CFS microbiome research therefore should not be limited to finding additional bacterial signatures. The field needs to separate microbial production from host utilization. Microbial gene abundance, active gene expression, metabolite production, epithelial transport, mitochondrial oxidation, intestinal oxygen gradients, bile-acid signaling, transit, barrier integrity and immune activation are separate layers of the same system.

A stool metabolite measurement represents the residue of flux. It reflects production, microbial reuse, epithelial absorption, transit and water handling. A relative bacterial abundance reflects community composition but not necessarily absolute biomass. A metabolic gene reflects capacity but not necessarily expression. A metabolite concentration reflects what remains in that compartment but does not necessarily reveal how much entered host tissue or how efficiently that tissue used it.

This case illustrates that problem particularly well. Butyrate represented a seemingly acceptable percentage of total SCFAs, yet the total SCFA pool itself was reduced and absolute butyrate was deficient. Looking only at percentage would have obscured the metabolic deficit. Looking only at the low absolute value would ignore severe dietary restriction and altered transit. Looking only at bacteria would miss the host side entirely.

The Host Capacity model is built around this distinction. The physiological effect of any microbial product depends on the capacity of the host receiving it. A resilient system can absorb metabolic perturbation, process the new substrate and return toward equilibrium. A severely constrained system may respond dramatically to even a small additional input because mitochondrial reserve, autonomic reserve, epithelial integrity, enzymatic clearance and immune thresholds are already operating close to their limits.

The goal in that situation is not simply to attack dysbiosis or replace what appears deficient. The goal is to understand the feedback loops maintaining the abnormal state and identify the bottlenecks that can be changed without exceeding the system’s remaining capacity.

The Guo study showed that deficient butyrate-producing capacity is a real finding in ME/CFS. This anonymized severe case shows what that phenotype can look like inside a person with long-standing autonomic dysfunction, profound gastrointestinal disturbance, severe food restriction, extreme treatment sensitivity and major loss of physiological reserve.

Neither finding proves that butyrate deficiency causes ME/CFS. What they support is a more interesting model in which, for at least some patients, microbial metabolic insufficiency and host metabolic incapacity may reinforce one another. The microbiome produces fewer metabolites required by the intestinal epithelium, while a metabolically impaired epithelium becomes less capable of maintaining the anaerobic ecological conditions required by the microbes that normally produce those metabolites.

Once that relationship begins to fail, the problem is no longer simply the presence or absence of particular bacteria.

The problem becomes a loss of metabolic cooperation between the intestinal ecosystem and the host.

That, in my view, is where the gastrointestinal biology of ME/CFS becomes much more important than a conventional stool report suggests.

Primary study discussed: Guo C, Che X, Briese T, et al. Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME/CFS. Cell Host & Microbe. 2023;31(2):288–304.e8. doi:10.1016/j.chom.2023.01.004.